Skip to main content
AMCP Nexus 2023 Main banner

Making the Way for Innovation

(W4) Biosimilar Operational Readiness: Managed Care Stakeholder Response to Market Expansion Impact

Wednesday, October 18, 2023
9:45 AM – 11:00 AM East Coast USA Time
Location: Royal
CPE
ACPE UAN:0233-0000-23-058-L04-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This activity is supported by independent medical education grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Coherus BioSciences, Inc.

With the emergence of biologics in the chronic inflammatory diseases space, all eyes are focused on the current and upcoming biosimilar pipeline. Many prominently used biologics have lost patent protection in 2023, paving the way for a new wave of biosimilars to flood the marketplace and to foster more competition than seen before in the biosimilar marketplace.

Managed care and other health professionals must monitor this unprecedented influx of biosimilars and its potential impact on pharmacy operations, patient care, and related cost savings.

This panel session will provide various managed care pharmacy perspectives on adjusting to the rapid biosimilar market expansion, including potential challenges and solutions.

Learning Objectives::

At the completion of this activity, participants should be able to:
  1. Summarize biosimilar concepts related to market competition, access, interchangeability, switching, and substitution.
  2. Identify evidence-based formulary considerations for the current biosimilar market, anticipated launches, and pipeline.
  3. Discuss the benefits and challenges of the biosimilar market expansion among key stakeholders.